on Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Announces Leadership Changes
Aspire Biopharma Holdings, Inc. has announced significant changes in its leadership. Kraig Higginson, who currently chairs the board, has been named interim CEO following the resignation of Michael C. Howe. Mr. Higginson has previously served as CEO for four years and will lead with the intent to maximize Aspire's drug delivery platform's potential. The board is initiating the search for a permanent CEO.
The company also announced the departure of board members Gary E. Stein and Barbara Sher. Howard Doss has been appointed Director and Chairman of the Audit Committee. Doss is a seasoned CFO with vast experience, having served in various financial roles, including at PowerUp and Kernel Group Holdings, Inc. He holds a degree from Illinois Wesleyan University and is affiliated with the American Institute of CPA's.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Aspire Biopharma, Inc. news